Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus BETADERM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus BETADERM.
ARAZLO vs BETADERM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Betamethasone dipropionate is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects through induction of phospholipase A2 inhibitory proteins (lipocortins) and inhibition of arachidonic acid release, thereby reducing prostaglandin and leukotriene synthesis.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Topical: Apply a thin film to affected skin twice daily; maximum 100 g per week for adults.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is approximately 18-36 hours (mean ~24 hours) following topical application; systemic half-life after oral administration is similar, reflecting prolonged tissue retention.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal excretion of metabolites (mainly as glucuronide and sulfate conjugates) accounts for approximately 60-70% of elimination; fecal/biliary excretion accounts for 30-40%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid